The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancer worldwide with an overall survival rate, all stages combined, of still

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2022-02, Vol.14 (4), p.995
Hauptverfasser:	Muller, Marie, Haghnejad, Vincent, Schaefer, Marion, Gauchotte, Guillaume, Caron, Bénédicte, Peyrin-Biroulet, Laurent, Bronowicki, Jean-Pierre, Neuzillet, Cindy, Lopez, Anthony
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptive immunology Adenocarcinoma Cancer CD4 antigen CD8 antigen Chemotherapy Dendritic cells Effector cells Fibroblasts Genotype & phenotype Human health and pathology Hypoxia Hépatology and Gastroenterology Immune checkpoint inhibitors Immunology Immunoregulation Infiltration Inflammation Life Sciences Lymphocytes Lymphocytes T Macrophages Medical prognosis Metastases Metastasis Pancreas Pancreatic cancer Pancreatic carcinoma Pancreatitis Patients Phenotypes Proteins Radiation therapy Review Stroma Suppressor cells Therapeutic applications Therapeutic targets Tumor cells Tumor microenvironment Tumors Vascularization
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancer worldwide with an overall survival rate, all stages combined, of still
ISSN:	2072-6694 2072-6694
DOI:	10.3390/cancers14040995